Sanofi, AstraZeneca back Teva's call to rehear case on patent listings
Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist five inhaler patents from the FDA’s Orange Book. The drugmakers, along with PhRMA and BIO, argued ...
Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist five inhaler patents from the FDA’s Orange Book.
The drugmakers, along with PhRMA and BIO, argued ...
